Towards gene-editing treatment for alzheimer's disease: ApoE4 allele-specific knockout using a CRISPR cas9 variant

      Background: The apolipoprotein E4 (ApoE4) is known as the most prevalent genetic risk factor for sporadic Alzheimer's disease (AD). More than 60% of these patients express the ApoE4 protein. This protein increases the risk of r AD by lowering the age of onset of the disease by as much as 10–20 years. Eliminating the expression of ApoE4 may prevent the development of this pathology.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect